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A b s t r a c t
Background: Bicuspid aortic valve (BAV) has been considered a relative contraindication for transcatheter aortic valve im-
plantation (TAVI). Due to more oval shape of the BAV annulus compared to tricuspid aortic valve, the procedure has been 
discouraged because of an increased risk of stent assembly displacement, uneven expansion, post-procedure paravalvular 
leakage, stent valve distortion, or other malfunction after implantation. For the same reasons patients with BAV have been 
excluded from the majority of clinical TAVI trials.
Aim: To evaluate the efficacy and safety of TAVI in patients with BAV stenosis. 
Methods: We analysed a group of 104 patients admitted to our institution for TAVI between January 2009 and May 2012. During 
pre-procedure evaluation, transthoracic and transoesophageal (TEE) echocardiography as well as angio-computed tomography 
(CT) scan were performed to assess aortic valve anatomy and morphology. Appropriate measurements and detailed analyses 
of imaging data have been accomplished to select optimal access site, prosthesis size as well as to plan the procedure. BAVs 
were recorded in seven patients (6.7%; mean age 77.7 years). These patients presented with severe symptomatic aortic 
valve stenosis with a mean aortic valve area of 0.55 cm2 (0.46–0.7 cm2) as measured in TEE. All of the patients had been 
disqualified from surgical valve replacement due to high surgical risk with a mean logistic Euroscore of 19.9%. All of them 
successfully underwent TAVI using CoreValve (n = 5) or Sapien (n = 2) valves. Follow-up was completed at 30 days, and six 
and 12 months after the procedure.
Results: During follow-up one patient developed an elliptic distortion of the aortic prosthesis in CT, although it did not result 
in significant malfunctioning of the implant. One patient died of infective endocarditis 30 days after the procedure. Survivors at 
30-day follow-up had mild to moderate aortic insufficiency, and it did not deteriorate after six months. At one year follow-up 
six out of seven patients remained alive. They achieved significant functional improvement by New York Heart Association 
class compared to baseline.
Conclusions: TAVI may constitute an alternative treatment option for high-risk patients with BAV, resulting in a low peripro-
cedural mortality rate, and good 30-day, six-month, and one-year outcomes.
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INTRODUCTION 
Bicuspid aortic valve (BAV) belongs to the most common 
cardiac congenital abnormalities diagnosed in approximately 
0.8–2% of the population [1, 2]. This anatomic variation is 
associated with higher risk of rapid leaflet degeneration and 
calcification leading to stenosis of the aortic orifice [3]. It 
often co-exists with dilatation of proximal thoracic aorta and 
precedes such adverse events as aneurysm formation and 
dissection or rupture of the main vessel [4]. There have been 
many surgical techniques and different therapeutic options 
for patients presenting with BAV stenosis with or without 
regurgitation [5]. With the advent of transcatheter valves 
specifically for minimally invasive implantation procedures, 
patients with aortic stenosis have benefited with a new thera-
peutic approach. Nevertheless, BAV has been considered an 
exclusion criterion in most randomised controlled trials [6]. 
Although this anomaly still remains a relative contraindication 
for transcatheter aortic valve implantation (TAVI) [7], there 
have been a number of cases presented worldwide in which 
patients successfully underwent TAVI in a native orifice of 
BAV [8–16].
Alternated anatomy of bicuspid aortic root causes cer-
tain problems with adequate stent-valve assembly position-
ing, deployment, and functioning. The anatomical features 
to be carefully evaluated before TAVI procedure are the 
existence of an elliptic shape of the aortic annulus and the 
presence of asymmetric heavy calcifications [4]. Multiscan 
computed tomography (MSCT) together with transthoracic 
(TTE) and transoesophageal (TEE) echocardiography yield 
an effective diagnostic approach to the management of BAV 
and allow the implantation to be properly planned [17]. 
Figures 1 and 2 show cross sectional views of stenotic BAV 
with marked calcification forming a calcium bridge along the 
raphe between the right and left aortic leaflets.
METHODS 
In this retrospective report we present the data of seven pa-
tients (72–85 years old, mean age 77.7 years, four females) 
with documented BAVs, admitted to the Institute of Cardiology 
in Warsaw. This cohort has been selected from the group of 
104 patients who underwent TAVI procedure in our institution 
between January 2009 and May 2012. All of the investigated 
patients presented with severe symptomatic aortic valve ste-
nosis (functional New York Heart Association [NYHA] class II 
to IV) with mean aortic valve area of 0.55 cm2 (0.46–0.7 cm2) 
and transaortic mean pressure gradient of 74.57 mm Hg 
(60–94 mm Hg) as measured in TEE. They were considered 
high surgical risk with an average calculated logistic Euroscore 
of 19.9% (5.8–33.09%), and they had been previously dis-
qualified from surgical aortic valve replacement (SAVR) by an 
institutional Heart Team. Every patient routinely underwent 
a pre-procedural diagnostic scheme based on TTE and TEE, 
MSCT scanning of heart and ascending aorta, as well as 
angio-MSCT of iliac and femoral arteries for proper planning 
of the valve implantation in terms of selection of access route, 
valve size, and complication risk assessment. Two patients suf-
fered from occlusive aortic sclerosis and were excluded from 
transfemoral approach. One patient had had an abdominal 
aortic aneurysm. One patient (with a relatively low log Euro-
score of 5.8%) had a history of oncologic disease and had 
undergone mastectomy and chest radiotherapy, which was 
an unfavourable factor for surgery. Finally, four patients were 
qualified for transfemoral approach, two for subclavian, and 
one for transapical access. The clinical characteristics of the 
patients are shown in Table 1.
Figure 1. Cross-sectional computed tomography (CT) scan of 
stenotic bicuspid aortic valve with marked calcification forming 
a calcium bridge along the raphe between the right and left 
aortic leaflets
Figure 2. Cross-sectional computed tomography scan of  
bicuspid aortic valve with no evident calcific raphe
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The aortic annulus diameter measured in TEE was 
22.9 mm (20–27 mm), but when measured by computed 
tomography (CT) it was 24.2 mm (22–26 mm — approximate 
diameter calculated as average of short and long diagonals). 
Both TEE and MSCT revealed massive calcifications and signifi-
cant thickening of the bicuspid valve leaflets in all presented 
cases. Five patients had an elliptic annulus shape, defined as 
a difference of ≥ 3 mm between the shortest and the long-
est diameters of the aortic annulus measured by MSCT in 
the plane of the lowest attachment points of the leaflets to 
the annulus (hinge points). Imaging features of the aorta and 
aortic valve are shown in Table 2.
RESULTS 
After diagnostic evaluation the patients were ultimately 
qualified for TAVI by the Heart Team. They were informed 
of the procedural details and risk. The details of the TAVI 
procedure have been described elsewhere [18, 19]. Written 
informed consent was given and signed by every patient and 
an operator. Five patients received CoreValve aortic prosthe-
ses (Medtronic, Inc., Minneapolis, MN, USA): 26 mm in one 
patient and 29 mm in four patients. In two other patients 
Sapien 23 mm valves were used (Edwards Life Sciences, 
Inc., Irvine, CA, USA). Transfemoral access was utilised in 
five patients, whereas the remaining two received transapical 
(one patient, Edwards Sapien valve) or trans-subclavian (one 
patient, CoreValve valve) approach. Another patient had been 
initially considered for trans-subclavian approach, but in the 
course of the procedure the surgically prepared left subclavian 
artery turned out to be too narrow to advance the CoreValve 
assembly (suspected vasoconstriction). Thus, conversion to 
femoral access was necessary. None of the patients required 
post-dilatation of the newly implanted prosthesis. Overall 
there was no intraprocedural death. All of the procedures were 
Table 1. Baseline characteristics of the patient group
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Patient number  
in case series
25 34 39 55 89 97 104
Age [years] 85 80 72 73 84 75 75
Gender Male Male Female Male Female Female Female
Medical history:
Previous MI Yes No Yes Yes No No No
PCI No No No No No No No
CABG No Yes No Yes No No No
Stroke/TIA No Yes No No No No No
Diabetes mellitus Yes Yes Yes Yes Yes No No
Obesity/MS Yes No Yes No Yes No No





















NYHA class III IV II IV III II II







SR; 1st AV 
block; LAH







LVEF [%] 60 43 65 60 55 70 60
Peak/mean TAVG 116/67 96/60
84/55
127/81 110/76 127/70 136/94 119/74
Mean logistic  
Euroscore [%]
15.7 33.1 27.5 32.22 12 5.8* 12.5
*Such a low logistic Euroscore does not fully reflect the high surgical risk of this patient, who had undergone mastectomy and chest radiotherapy, 
and had suffered from osteoporosis. 
AO — atherosclerosis obliterans; AV block — atrioventricular block; CABG — coronary artery bypass graft; CCS — Canadian Cardiovascular  
Society; LAH — left anterior hemiblock; LVEF — left ventricular ejection fraction; MI — myocardial infarction; MS — metabolic syndrome;  
NYHA — New York Heart Association; PCI — percutaneous coronary intervention; RBBB — right bundle branch block; SR — sinus rhythm;  
TAVG — transaortic valvular gradient; TIA — transient ischaemic attack
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successful in terms of direct reduction of aortic transvalvular 
gradient. Device success and end-point definitions were 
adapted from the consensus report according to the Valvular 
Academic Research Consortium [20]. Adverse events were 
prospectively recorded at hospitalisation for index procedure, 
at 30-day, six-month, and one-year medical visits at our 
institutional ambulatory care unit or via telephone contact. 
Table 3 presents outcome assessed by echocardiography dur-
ing index procedure hospitalisation or at discharge.
In general TAVI yielded effective transvalvular gradient 
reduction evaluated by TTE. Maximal and mean gradient 
dropped from 117.86 mm Hg to 20.87 mm Hg (range: 
6.3–36 mm Hg) and from 74.57 mm Hg to 11.36 mm Hg 
(range: 0–16 mm Hg), respectively. Post-procedure aortic 
valve insufficiency (paravalvular leak) in the entire cohort was 
mild to moderate, not significantly varying from the values 
observed in our experience after TAVI in tricuspid aortic valves 
[21]. In the remaining 97 consecutive patients (with tricuspid 
aortic valves), who were treated in our centre within the same 
timeframe, two patients had unsuccessful procedure and six 
died in the hospital.
During 30-day follow-up functional NYHA class improved 
by one in four out of seven patients. The lack of improve-
ment in three patients can be explained by the fact that one 
of them was highly inefficient due to complications (deep 
venous thrombosis and infective endocarditis), whereas two 
others had presented with good NYHA class from the begin-
ning (NYHA II), so clinical improvement was not so evident.
Two patients needed an additional CT scan after the 
procedure because of suspicion of asymmetric deployment or 
underexpansion of the stented valve. In one case (patient no. 1) 
it was confirmed and visualised at three weeks after TAVI as el-
liptic distortion of the stent-valve assembly (CoreValve 26 mm). 
Figures 3 and 4 show deformation of the lower part of the stent 
with an asymmetric size of 24 × 7 mm. The distortion resulted 
in moderate paravalvular aortic regurgitation but decreased to 
mild at 90-day follow-up without further sequelae. Due to the 
good physical condition of the patient and the lack of a need for 
further evaluation another CT-scan was not performed.
In a second case (patient no. 4), after implantation of an 
Edwards Sapien 23-mm valve via transapical route, repeated 
CT scan revealed the correct position of the prosthetic valve 
Table 2. Imaging characteristics of the aorta and aortic valve
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
AVA [cm2] (TEE) 0.5 0.7 0.6 0.7 0.46 0.51 0.52
TEE — AoVAn [mm] 23 27 24 22 22 20 20
MSCT — AoVAn (short 
and long axis) [mm]
20 × 29 22 × 29 24 × 25 22 × 25 24 × 28 21 × 23 20 × 27
Elliptic annulus Yes Yes No Yes Yes No Yes
MSCT — SoV [mm] 31 34 × 40 27 39 39 28 31 × 26
MSCT — STJ [mm] 24 36 × 33 32 31 35 24 26
AsAo [mm] 34 40 × 39 39 35 50 29 30 × 30
Prosthetic valve type  
and size [mm]
CV 26 CV 29 CV 29 ES 23  
(transapical)
CV 26 SXT 23 CV 29 
AoVAn — aortic valve annulus diameter measured across the root of the aorta from the basal attachment of two leaflets (hinge point); AsAo — 
ascending aorta diameter; AVA — aortic valve area; CV — CoreValve; ES — Edwards Sapien; MSCT — multiscan computed tomography; SoV — 
sinus of Valsalva diameter; STJ — sinotubular junction diameter; SXT — Sapien XT; TEE — transoesophageal echocardiography
Table 3. Echocardiographic characteristics of the patients after the procedure
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Peak/mean TAVG 
[mm Hg]
41/23 13.5/6.3 26/15 (slightly 
atypical position of 
prosthetic valve)
31.4/18.5 21.2/13.9 30/14.7 20/–
Paravalvular 
regurgitation
Moderate Moderate Mild Mild Mild Mild Trivial
Transvalvular 
regurgitation
None None None Trivial Trivial None Mild
LVEF [%] 65 45 64 65 65 70 65
LVEF — left ventricular ejection fraction; TAVG — transaortic valvular gradient
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and slightly elliptic shape of the frame (25 × 21 mm) cor-
relating with annulus deformation (Fig. 5A, B). No significant 
malfunction of the prosthetic valve was observed. At six-month 
follow-up in TTE good valve function was sustained with 
a mean transvalvular gradient of 19 mm Hg and only mild 
paravalvular and trivial transvalvular regurgitant jets.
Another deformation of a stented valve (CoreValve; 
patient no. 3) was also suspected upon TTE, but because of 
good clinical and haemodynamic results the CT scan was not 
repeated and the patient remained well. What is interesting 
in this case is the slight elliptic deformation of the prosthetic 
valve in spite of a regular shaped annulus as assessed on MSCT 
before the procedure. The distortion, however, may result 
from massive calcification of the native leaflets. Nevertheless, 
it did not seem to have an impact on the clinical outcome. 
Two patients required pacemaker implantation because 
of bradycardia (sick sinus syndrome) or advanced atrioven-
tricular block. One of them developed infective endocarditis 
on pacemaker electrodes, which progressed to a major para-
valvular leak, and died 30 days after the index procedure. 
One patient developed access site bleeding requiring trans-
fusion of two units of packed red blood cells (patient no. 6). 
Table 4 presents 30-day follow up, including complications 
since the index procedure. 
Six and 12 months after the procedure all six survivors 
remained alive and did not develop any further complica-
Figure 3. Cross-sectional computed tomography scan visua-
lising elliptic distortion of the CoreValve aortic bioprosthesis 
(patient no. 1)
Figure 4. Computed tomography scan — longitudinal section 
visualising elliptic distortion of the CoreValve aortic bioprosthesis 
(patient no. 1)
Figure 5. A, B. Good alignment of an Edwards Sapien 23 mm prosthetic valve in a patient with massive calcification of bicuspid 
aortic valve. Calcific tissue of native leaflets pushed aside of the bioprosthesis
A B
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tions. Table 5 presents clinical and echocardiografic six-month 
follow-up. The patients were free of major cardiac adverse 
events and none of them required hospitalisation due to 
cardio vascular causes. Five patients achieved further improve-
ment in NYHA class and presented hardly any symptoms 
of heart failure. One patient remained in NYHA class I (no 
change compared to 30-day follow up). Four patients had 
just a slight improvement (by ½ class), whereas one patient 
presented dramatic improvement from NYHA III to NYHA 
I (patient no. 4). This is the patient who had been treated with 
transapical approach, and his belated progress in overall ef-
ficiency may be explained by gradual wound healing and slow 
return to normal daily activity. It should be mentioned that 
patients five and six reported poor mobility due to osteoporo-
sis and multiple articulation pains, respectively; nevertheless, 
they denied dyspnoea or ankle swelling.
DISCUSSION
Bicuspid aortic valve accounts for a considerable number of 
patients operated on due to severe aortic stenosis. Accord-
ing to available data the frequency varies between 30% and 
50% of all adult SAVRs [3, 22]. Although this common cardiac 
anomaly remains a relative contraindication to TAVI, selected 
patients may take advantage of this less invasive method [12].
Table 4. Thirty-day follow-up
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7









LVEF [%] 72 40–45 66 65 70 70 65






























None DVT; implanted 










two units of PRBC
LBBB
DVT — deep venous thrombosis; IE — infective endocarditis; LBBB — left bundle branch block; LVEF — left ventricular ejection fraction; NYHA — 
New York Heart Association; PRBC — packed red blood cells; TAVG — transaortic valvular gradient
Table 5. Six-month follow-up
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Peak/mean TAVG 
[mm Hg]
*65.5/26.7 This patient died 
because of IE 
30 days after TAVI
32.5/15 37/19 6/– 14/9 21/–





Trivial/mild Mild  
(transvalvular)
LVEF [%] 70 70 60 66 65 65
Prosthetic valve  
malapposition/ 
/deformation
As previously – – – – –
Complications – – – – – –











I (no change) I/II (improved 
from NYHA II)
*This TTE shows increased TAVG, but after 12 months 38/16 mm Hg; IE — infective endocarditis; LVEF — left ventricular ejection fraction;  
NYHA — New York Heart Association; TAVG — transaortic valve gradient; TAVI — transcatheter aortic valve implantation; TEE — transoesophageal  
echocardiography
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Some specific facts must be taken into consideration 
before qualifying a BAV stenotic patient to TAVI. Due to 
the more oval shape of the aortic annulus compared to 
tricuspid aortic valves [23], an operator may expect difficul-
ties with proper expansion and effective sealing of the valve 
prosthesis. Accurate assessment of native valve morphology 
is crucial for TAVI planning. BAVs, especially with bulky 
leaflets, enlarged aortic roots, dilated ascending aorta, and 
significant aortic incompetence might cause difficulties with 
positioning and deploying a valve prosthesis [24]. Little is 
also known about valve sizing criteria in the setting of elliptic 
annulus shape. Among the cases presented in this article the 
patient, who developed elliptic distortion of an aortic valve 
prosthesis, was supplied with seemingly adequate valve size 
— CoreValve 26 mm — based on TEE measurements (aortic 
valve annulus 23 mm). However, the longest diameter of 
elliptic annulus assessed by MSCT was 29 mm. It is not fully 
understood whether larger valve diameter ensures better 
sealing, preserves distortion or malfunction, and maintains 
the same safety of procedure as smaller size. In such a case, 
spontaneous reduction of paravalvular leakage within several 
months (from moderate to mild) is undoubtedly noteworthy. 
One may suspect gradual adaptation of perivalvular tissue that 
enhances proper sealing. It can also be considered that, espe-
cially with self-expandable CoreValve valves, a self-adaptive 
mechanism of nitinol frame may compensate over time for 
uneven diameters of oval BAV annuli.
Recently a new method of valve sizing has been pro-
posed. In contrast with the traditionally used valve sizing 
based on diameter measurements, this new method is based 
on the perimeter of the aortic annulus measured on CT-scan 
[25]. The authors describe the dynamic on conformational 
changes that occur throughout the cardiac cycle of the aortic 
annulus, reshaping its elliptical shape in diastole to a more 
rounded shape in systole, to increase the cross-sectional flow 
area. This change occurs without a significant variation in the 
perimeter size, especially in patients with calcific aortic steno-
sis. Perimeter changes are negligible in patients with calcified 
valves, because tissue properties allow very little expansion. 
Aortic annulus perimeter appears therefore ideally suited for 
accurate sizing in TAVI.
In our cases TEE and average CT-based diameter were 
utilised for prosthesis sizing. Now we have re-evaluated our 
cases in order to check which prosthesis size would have been 
selected if sizing had been based on the perimeter of the aor-
tic annulus. The results of the analysis are shown in Table 6.
The first thing to note is the discrepancy between selected 
prosthetic valve size and estimation based on aortic annulus 
perimeter. Four out of seven patients would have received 
different prosthetic valves than actually chosen (three — larger, 
one — smaller). Interestingly, patient no. 5 had the most ex-
plicit discrepancy — by estimation she would receive a Core-
Valve 31 whereas she actually received a CoreValve 26. This 
is the patient who presented with significantly dilated aorta 
(50 mm). In such cases we bear in mind the risk of aortic 
regurgitation and problems with proper anchorage of the pros-
thesis. However, none of that happened in this patient (she 
developed mild aortic regurgitation at most). We may suspect 
that this is because of a relatively small sinotubular junction 
diameter (35 mm) compared to ascending aorta diameter. 
We are not sure if perimeter-based sizing would result in 
better patient outcome, if utilised in BAV patients. Similarly, 
we can only guess if one case of the elliptic distortion of pros-
thetic valve (patient no. 1) could have been avoided if a larger 
valve had been selected. Further investigation is needed to 
evaluate the perimeter based sizing method compared to CT 
diameter sizing.
Another topic for discussion is the type of prosthesis 
preferably dedicated for BAVs. Some clinicians claim that 
the Sapien XT is contraindicated in the setting of BAV in 
spite of several successful implantations having been done in 
recent years [9, 14]. Basically, balloon-expanded valves show 
higher radial strength directly after implantation whereas the 
self-expanding nitinol stents reveal unique properties reported 
as shape memory or so-called superelasticity, which lead 
to an increase in maximal radial force with the passage of 
Table 6. Prosthesis sizing based on aortic annulus perimeter
Patient no. Annulus  
diameter  
in TEE [mm]
Aortic annulus  
diameters  
in CT [mm]
Aortic annulus  
perimeter  
in CT [cm]
Chosen valve  
size
Valve size chosen  
if perimeter  
sizing utilised
1 23 29 × 20 8.22 CV 26 29!
2 27 29 × 22 8.25 CV 29 29
3 23 25 × 24 8.09 CV 29 29
4 22 25 × 22 7.48 ES 23 26!
5 22 28 × 24 8.41 CV 26 31!
6 20 23 × 21 6.98 ES 23 23
7 23 27 × 20 6.96 CV 29 26!
CT — computed tomography; CV — CoreValve; ES — Edwards Sapien; TEE — transoesophageal echocardiography
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time [26]. The long aortic cuff of the CoreValve system may 
show particular benefit when anchoring in a widened aortic 
root, which is commonly associated with BAV. We could 
clearly observe how well it applied to patient no. 5, who suf-
fered from an aortic aneurysm and gained sustained clinical 
benefit owing to CoreValve implantation. On the other hand 
the literature presents a case of unsuccessful implantation of 
the Sapien system in the setting of ascending aortic aneurysm 
(the prosthesis did not anchor adequately) [27].
It is hard to reliably compare self-expanding valves (Core-
Valve) with the balloon-expandable system (Sapien XT). Our 
small cohort study indicates that two self-expanded biopros-
theses underwent distortion and two others caused need for 
pacemaker implantation, whereas there were no complications 
of this kind with two Sapien valves. However, six and 12 months 
after implantation we observed clinical improvement of at least 
one NYHA class in all treated patients (except the one who died 
after 30 days) irrespective of valve type used.
The other important issue is long-term follow-up after 
TAVI in BAVs. Distortion of the valve-stent assembly and 
non-uniform stent expansion may potentially lead to pros-
thetic valve malfunction with time. Although we did not 
observe any of this in our cohort we cannot definitely exclude 
the escalation of paravalvular leaks.
Further data is needed to compare the systems and 
achieve long-term follow-up in comparison to TAVI performed 
in tricuspid aortic valves.
Limitations of the study
This is a retrospective analysis of a small patient cohort treated 
at a single clinical centre. No systematic approach was utilised. 
The study included patients with BAV of unconfirmed origin 
(congenital and degenerative taken together). Two different 
prosthetic valve types were assessed, which makes the com-
parison of outcomes unreliable.
CONCLUSIONS 
Transcatheter aortic valve implantation, using either Sapien 
or CoreValve systems, may constitute an alternative treatment 
option for patients with BAV and high surgical risk. TAVI 
is feasible and effective in this group of patients, resulting 
in low periprocedural mortality rate and good 30-day and 
one-year outcomes. Further studies with larger patient co-
horts are needed to confirm long-term efficacy of implanted 
valves. Nonetheless, thorough pre-procedure planning, 
involving echocardiography and CT, and more gathered 
experience is needed to master the differences in technique 
and postoperative care between bicuspid and tricuspid valve 
patients treated with TAVI.
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Przezcewnikowa implantacja zastawki aortalnej  
u pacjentów z zastawką dwupłatkową:  
seria przypadków
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S t r e s z c z e n i e
Wstęp: Obecność dwupłatkowej zastawki aortalnej (BAV) uważa się za względne przeciwwskazanie do zabiegu przezcew-
nikowej implantacji zastawki aortalnej (TAVI), a leczenie chirurgiczne pozostaje metodą z wyboru w przypadku jej ciasnego 
zwężenia. Procedura TAVI nie jest zalecana w tej grupie chorych m.in. ze względu na owalny kształt pierścienia zastawki dwu-
płatkowej w porównaniu z pierścieniem prawidłowej (trójpłatkowej) zastawki, co zwiększa ryzyko dysfunkcji i zniekształcenia 
protezy. Dwupłatkowa zastawka aortalna stanowiła kryterium wyłączenia w większości badań klinicznych dotyczących TAVI 
i brakuje dokładnych danych na temat bezpieczeństwa i skuteczności takiego postępowania w tej grupie chorych.
Cel: Celem pracy była ocena bezpieczeństwa i skuteczności TAVI u pacjentów z ciasnym zwężeniem BAV.
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Metody: Analizie poddano grupę 104 pacjentów przyjętych do Instytutu Kardiologii w celu wykonania TAVI w okresie od 
stycznia 2009 r. do maja 2012 r. W ramach kwalifikacji do zabiegu wykonano echokardiograficzne badania przezklatkowe 
i przezprzełykowe oraz tomografię komputerową serca, aorty i jej rozgałęzień. Odpowiednie pomiary i analiza danych z badań 
obrazowych umożliwiły wybór optymalnego dostępu przeznaczyniowego, dobranie protezy zastawkowej i właściwe zapla-
nowanie zabiegu. Dwupłatkową zastawkę aortalną zidentyfikowano u 7 pacjentów (6,7%; średni wiek 77,7 roku), których 
poddano bardziej szczegółowej analizie. Pacjenci ci mieli zdiagnozowaną ciasną objawową stenozę aortalną ze średnim polem 
powierzchni przekroju zastawki 0,55 cm2 (0,46–0,7 cm2). Wszyscy zostali zdyskwalifikowani z zabiegu chirurgicznej wymiany 
zastawki aortalnej ze względu na wysokie ryzyko operacyjne (uśredniony wynik logistic Euroscore 19,9%). Wykonano TAVI 
z wykorzystaniem systemow CoreValve (5 osób) lub Sapien (2 chorych). Następnie przeanalizowano prospektywne wyniki dłu-
goterminowej obserwacji klinicznej i echokardiograficznej w punktach czasowych: 30 dni, 6 miesięcy i 12 miesięcy po zabiegu.
Wyniki: U 1 pacjenta w tomografii komputerowej zaobserwowano eliptyczne zniekształcenie implantowanej protezy, jednak 
bez istotnej klinicznie dysfunkcji zastawki. Jeden pacjent zmarł w ciągu 30 dni po TAVI z powodu infekcyjnego zapalenia 
wsierdzia. Pozostali, którzy przeżyli, charakteryzowali się małą do umiarkowanej niedomykalnością aortalną w punkcie cza-
sowym wynoszącym 30 dni. W kolejnych punktach czasowych nie zaobserwowano progresji niedomykalności aortalnej. Po 
roku od zabiegu 6 spośród 7 pacjentów pozostawało przy życiu. Wszyscy oni osiągnęli istotną poprawę funkcjonalną ocenianą 
wg klasyfikacji New York Heart Association.
Wnioski: Zabieg TAVI może stanowić alternatywną opcję terapeutyczną dla pacjentów z ciasną stenozą BAV. Według ob-
serwacji autorów niniejszej pracy metoda ta cechuje się względnie niską śmiertelnością i dobrymi wynikami w obserwacji 
30-dniowej, 6- oraz 12-miesięcznej.
Słowa kluczowe: TAVI, przezcewnikowa implantacja zastawki aortalnej, stenoza aortalna, dwupłatkowa zastawka aortalna, 
zniekształcenie eliptyczne
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